TNF Inhibitors and TB Reactivation: Screening and Monitoring
TNF inhibitors effectively treat autoimmune diseases but carry a serious risk of reactivating latent tuberculosis. Screening with TST or IGRA, treating latent infection, and ongoing symptom monitoring are essential to prevent life-threatening TB. Risk varies by drug class, with infliximab and adalimumab posing the highest threat.